Bones and Joints
Medical Studies on DHEA – Bones and Joints
Especially in advanced age, bone health, and that of the musculoskeletal system, is an essential factor for lasting quality of life. In this respect, DHEA provides an important contribution and has already proven its worth, both for joint discomfort and for increasing bone density.
DHEA Inhibits Inflammatory Cytokines
Musculoskeletal disorders in old age are among the most common causes of mortality. Therefore, protecting bones and joints is an important task, which DHEA fulfills perfectly by inhibiting proinflammatory cytokines, thus contributing significantly to the improvement of age-related joint discomfort, such as that experienced with osteoarthritis. Studies show that even a few months of treatment with DHEA can produce good results.
Promotion of Healthy Osteoblast Activity
In addition, DHEA also has positive effects when it comes to maintaining healthy bone density. This is because it supports healthy osteoblast activity and increases the expression of insulin-like growth factor I, which has also been shown in several studies to improve fracture healing.
Medical Studies on DHEA – Bones and Joints
In vitro and in vivo tenocyte-protective effectiveness of dehydroepiandrosterone against high glucose-induced oxidative stress
Dehydroepiandrosterone (DHEA), an adrenal steroid, has a protective role against diabetes. This study aimed to investigate the in vitro and in vivo protective effects of DHEA against high glucose-induced oxidative stress in tenocytes and tendons.
The aging GABAergic system and its nutritional support
Aging is associated with a decline in hormones and an associated decline in GABAergic function and calcium and ion current dysregulation. Neurosteroid hormones act as direct calcium channel blockers, or they can act indirectly on calcium channels through their interaction with GABA receptors.
Cortisol and dehydroepiandrosterone response to adrenocorticotropic hormone and frailty in older women
The response to adrenocorticotropic hormone (ACTH) is poorly characterized in old-old adults and may provide insight into the physiologic response to stress.
Impact of dehydroepiandrosterone (DHEA) on bone mineral density and bone mineral content in a rat model of male hypogonadism
The present study examined the effect DHEA (dehydroepiandrosterone) on bone mineral content (BMC) and bone mineral density (BMD) and biomarkers of bone remodeling in orchidectomized male rats.
Dehydroepiandrosterone and age-related musculoskeletal diseases: connections and therapeutic implications
Musculoskeletal disorders related to ageing are one of the most common causes of mortality and morbidity among elderly individuals worldwide.
DHEA in bone: the role in osteoporosis and fracture healing
Dehydroepiandrosterone (DHEA) is a metabolic intermediate in the biosynthesis of estrogens and androgens with a past clouded in controversy and bold claims.
Supplementation of dehydroepiandrosterone (DHEA) in pre- and postmenopausal women – position statement of expert panel of Polish Menopause and Andropause Society
Dehydroepiandrosterone (DHEA) concentration decreases with age, therefore, DHEA has been considered a hormone that reduces the symptoms associated with aging, so the usefulness of DHEA in premenopausal and postmenopausal women, and the options of hormone therapy have received a large amount of attention.
Dehydroepiandrosterone sulfate and free testosterone but not estradiol are related to muscle strength and bone microarchitecture in older adults
The study aimed to elucidate the relationship between sex steroids and muscle mass, muscle strength, and trabecular bone score (TBS) in a community-dwelling aged population.
The effect of long-term DHEA treatment on glucose metabolism, hydrogen peroxide and thioredoxin levels in the skeletal muscle of diabetic rats
Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone involved in a number of biological actions. This study shows the effects of DHEA on glucose metabolism, hydrogen peroxide and thioredoxin levels in the skeletal muscle of control and diabetic rats.
Suppression of aggrecanase: a novel protective mechanism of dehydroepiandrosterone in osteoarthritis?
Aggrecanase-mediated aggrecan degradation is a significant event in the early stages of osteoarthritis (OA). There has been much interest in the possible role of these aggrecanases, mainly aggrecanase-1 (ADAMTS4) and aggrecanase-2 (ADAMTS5), as therapeutic targets in OA.
Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone
Age-related reductions in serum dehydroepiandrosterone (DHEA) concentrations may be involved in bone mineral density (BMD) losses.
Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens
The mechanisms by which dehydroepiandrosterone (DHEA) replacement increases bone mineral density (BMD) in older adults are not known.
Dehydroepiandrosterone treatment in the aging male – what should the urologist know?
Dehydroepiandrosterone (DHEA) has attracted considerable attention as a means against the decrements of aging. This review will summarize clinical studies evaluating DHEA as a treatment option for age-related conditions and diseases.
Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study
It has been suggested that the reduced production of dehydroepiandrosterone sulfate (DHEAS) may be partially responsible for the decline of muscle strength and mass that often occurs with aging. However, this hypothesis has been only tested in small series of normal volunteers, with little consideration for potential confounders.
The in vitro effects of dehydroepiandrosterone on human osteoarthritic chondrocytes
To investigate the in vitro effects of dehydroepiandrosterone (DHEA) on human osteoarthritic chondrocytes.
Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts
A significant positive correlation between bone mineral density (BMD) and serum dehydroepiandrosterone sulfate (DHEA-S) was found in 120 postmenopausal women (51–99 years old) but no correlation was seen between BMD and serum estradiol.